Saniona AB
The answer first
Does Saniona beat the market?
No, Saniona has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 65% of Nordic stocks
- Quality96
- Value52
- Trend27
No. 42 of 195 in healthcare
Expectations in the price
Low expectations
For the share to return about 9% a year from today's price, it is enough that the cash Saniona keeps shrinks about 6% a year for 10 years.
Max for seven days
Follow Saniona with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Saniona
Your first answer is free, no account needed.
Do you own Saniona, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Saniona and a few more. Free, no card.
Super Stock+44.6%In short
- Saniona has fallen 29.2% over the past year, including dividends.
- Overall, Saniona ranks better than 65% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 91.5%. The price is 73.8% below its peak now.
What do analysts think of Saniona?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 65% of Nordic stocks.
No. 42 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 14 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.00
- Asset turnoverSales divided by everything the company owns0.71
- Return on equityProfit divided by equity+33.5%
- Cash conversionOperating cash flow divided by profit1.06
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 49 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity2.8
- P/SPrice divided by sales3.6
- P/EPrice divided by earnings8.3
- P/CFPrice divided by operating cash flow7.8
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 107 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−4.1%
- 6 months−15.1%
- 9 months−53.1%
- 12 months−29.2%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Saniona
7 funds we follow own Saniona. The share is how much of the fund the stock makes up.
- Norway1
- Sweden6
- PLUS Mikrobolag Sverige IndexSweden · PLUS1.1%
- PLUS Hälsovård Sverige IndexSweden · PLUS0.5%
- Handelsbanken Norden Ind Crit (A1 NOK)Sweden · Handelsbanken0.1%
- Skandia Småbolag Sverige Exponering ASweden · Skandia0.1%
- Skandia Sverige ExponeringSweden · Skandia0.0%
- KLP AksjeNorden IndeksNorway · KLP0.0%
- Skandia Världen SverigeSweden · Skandia0.0%
From the funds' latest known holdings.
About Saniona
Saniona AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 44 employees.
Saniona AB (publ), a clinical-stage biopharmaceutical company, focuses on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders in Ireland, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy that has completed Phase 2 clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome; ACP-711, a positive allosteric modulator of GABAA a3 containing receptors that has completed…


See the full analysis of Saniona.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card